Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Novartis AG ADR (NYSE: NVS) closed the day trading at $124.21 up 1.74% from the previous closing price of $122.09. In other words, the price has increased by $1.74 from its previous closing price. On the day, 1.18 million shares were traded. NVS stock price reached its highest trading level at $124.31 during the session, while it also had its lowest trading level at $122.56.
Ratios:
For a better understanding of NVS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 33.67 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.13. For the most recent quarter (mrq), Quick Ratio is recorded 0.62 and its Current Ratio is at 0.82. In the meantime, Its Debt-to-Equity ratio is 0.78 whereas as Long-Term Debt/Eq ratio is at 0.57.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 23 ’25 when Marshall Fiona bought 15,000 shares for $112.68 per share.
Kowalski Robert William bought 1,212 shares of NVS for $137,297 on Apr 30 ’25.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVS now has a Market Capitalization of 240451928064 and an Enterprise Value of 266426318848. As of this moment, Novartis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.99, and their Forward P/E ratio for the next fiscal year is 13.43. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.28. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.40 while its Price-to-Book (P/B) ratio in mrq is 5.73. Its current Enterprise Value per Revenue stands at 4.828 whereas that against EBITDA is 11.312.
Stock Price History:
The Beta on a monthly basis for NVS is 0.62, which has changed by 0.07142246 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, NVS has reached a high of $124.83, while it has fallen to a 52-week low of $96.06. The 50-Day Moving Average of the stock is 4.71%, while the 200-Day Moving Average is calculated to be 13.26%.
Shares Statistics:
Over the past 3-months, NVS traded about 1.59M shares per day on average, while over the past 10 days, NVS traded about 1602640 shares per day. A total of 1.94B shares are outstanding, with a floating share count of 1.90B. Insiders hold about 0.00% of the company’s shares, while institutions hold 7.11% stake in the company. Shares short for NVS as of 1753920000 were 4377907 with a Short Ratio of 2.75, compared to 1751241600 on 4060960. Therefore, it implies a Short% of Shares Outstanding of 4377907 and a Short% of Float of 0.22999999999999998.
Dividends & Splits
NVS’s forward annual dividend rate is 3.87, up from 3.862 a year ago. Against a Trailing Annual Dividend Yield of 0.031632405The stock’s 5-year Average Dividend Yield is 3.63. The current Payout Ratio is 55.42% for NVS, which recently paid a dividend on 2025-03-12 with an ex-dividend date of 2025-03-12. Stock splits for the company last occurred on 2019-04-09 when the company split stock in a 1116:1000 ratio.
Earnings Estimates
Novartis AG ADR (NVS) is presently subject to a detailed evaluation by 2.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $2.02, with high estimates of $2.03 and low estimates of $2.01.
Analysts are recommending an EPS of between $9.26 and $8.71 for the fiscal current year, implying an average EPS of $9.02. EPS for the following year is $9.31, with 8.0 analysts recommending between $9.89 and $8.95.
Revenue Estimates
4 analysts predict $13.69B in revenue for the current quarter. It ranges from a high estimate of $13.91B to a low estimate of $13.38B. As of the current estimate, Novartis AG ADR’s year-ago sales were $12.82BFor the next quarter, 4 analysts are estimating revenue of $13.58B. There is a high estimate of $13.96B for the next quarter, whereas the lowest estimate is $13.04B.
A total of 15 analysts have provided revenue estimates for NVS’s current fiscal year. The highest revenue estimate was $57.96B, while the lowest revenue estimate was $52.72B, resulting in an average revenue estimate of $54.97B. In the same quarter a year ago, actual revenue was $50.32BBased on 15 analysts’ estimates, the company’s revenue will be $56.19B in the next fiscal year. The high estimate is $60.66B and the low estimate is $52.52B.
